PHARMAC have announced CGM funding for people with Type 1 diabetes from 1 October 2024. More detail to come.Additional information on Diabetes New Zealand website and the Pharmac Websites
You have nothing in your cart.
If you know the product code enter it here
If you know the product code enter it into the search field
Purified Non-muscle Myosin Heavy Chain II-A, 100 μl
Purified Non-muscle Myosin Heavy Chain II-B, 100 μl
Recombinant Human APP751, 25 µg
Recombinant Human APP770, 25 µg
Recombinant Human Tau-352 (0N3R), 25 µg
Recombinant Human Tau-381 (1N3R), 25 µg
Recombinant Human Tau-383 (0N4R), 25 µg
Recombinant Human Tau-410 (2N3R), 25 µg
Recombinant Human Tau-412 (1N4R), 25 µg
Recombinant Human Tau-441 (2N4R), 25 µg
Ultra-LEAF™ Purified anti-CD325 (N-Cadherin), 100 µg
Ultra-LEAF™ Purified anti-Glutamic Acid Decarboxylase (GAD65/GAD2), 100 µg
Ultra-LEAF™ Purified anti-Histone Lysine Demethylase (NO66), 100 µg
Ultra-LEAF™ Purified anti-human CD183 (CXCR3), 100ug
Ultra-LEAF™ Purified anti-mouse CD279 (PD-1) Antibody, 5 mg
Ultra-LEAF™ Purified anti-Syntrophin, 100 µg